|Bid||46.60 x 800|
|Ask||46.63 x 1200|
|Day's Range||45.90 - 46.22|
|52 Week Range||40.00 - 46.60|
|Beta (3Y Monthly)||0.40|
|PE Ratio (TTM)||23.82|
|Forward Dividend & Yield||1.74 (3.74%)|
|1y Target Est||52.00|
Top Trending: Abbott and Sanofi team up to help diabetes patients, Boeing’s board expected to reconsider engineering, and NBA's Raptors to introduce sports hijab for women.
Guggenheim analysts upgraded both Sanofi and Regeneron in part because of optimism about an antibody drug that treats a range of diseases on which the two companies have collaborated.
Sanofi (SNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Class-action law firm Hagens Berman has filed a second lawsuit regarding Sanofi and Boehringer Ingelheim’s intentionally concealed cancer risks in its popular heartburn medication, Zantac. Attorneys are also calling the Food and Drug Administration’s consumer-facing recommendations regarding the instance of a carcinogenic chemical in Zantac “highly questionable,” and are urging those who take Zantac to consult with their doctors before continuing to take the medicine.
Stock indexes reversed lower Friday afternoon, as the market for a second straight day seemed unable to hold early advances. The S&P; 500 today and other indexes fell sharply at 1:15 p.m. ET.
(Bloomberg) -- A global effort to remove gastrointestinal medication tainted with a potential carcinogen from the market gained momentum, as one of India’s largest generic drugmakers halted shipments to customers worldwide and Italy ordered a recall of some medicine that originated in India.Dr. Reddy’s Laboratories Ltd. said it is suspending all distribution of its ranitidine, the generic version of the Sanofi stomach drug Zantac, as a precautionary measure. The company expects “to provide an update in the coming days,” said spokeswoman Lori McCreary in an email.Separately, the Italian Drug Agency said in a statement it was ordering a recall of all versions of Zantac with active ingredient made by the India-based firm Saraca Laboratories Ltd. Italian regulators also banned the use of some types of Zantac produced by other pharmaceutical companies pending analysis of the drugs.U.S. and European Union regulators said last week they were investigating the discovery of the carcinogen NDMA, or N-Nitrosodimethylamine, in branded and generic Zantac. The regulators said they hadn’t ascertained how the drugs came to be contaminated. In the U.S., the Food and Drug Administration has so far left the drugs on the market.NDMA was also detected in a commonly prescribed class of blood-pressure drugs, leading to the recall of millions of pills in 30 countries beginning in July of last year. In addition to the Italian drug agency, Germany’s drug regulator indicated earlier this week there were wider recalls of ranitidine made with active ingredient from Saraca in Europe. Saraca supplies larger drugmakers that make the pills sold to patients.Health officials in Canada have asked all makers of ranitidine to stop distribution of the heartburn treatment in that country.Novartis AG’s generic-drug unit, Sandoz, halted global distribution on Wednesday of its generic Zantac, known as ranitidine. Brand-name Zantac maker Sanofi hasn’t halted distribution of the drug or any of its other ranitidine products outside of Canada. About two dozen generic drugmakers are FDA-approved to sell their own versions of prescription and over-the-counter Zantac in the U.S., including Sandoz and Dr. Reddy’sBloomberg News has reported on how poor quality controls and efforts to conceal manufacturing problems from the FDA have complicated oversight of overseas drug producers.As regulators deal with the Zantac investigation, the worldwide recall of tainted blood-pressure pills known as angiotensin II receptor blockers, or ARBs, is still widening. On Thursday, India-based Torrent Pharmaceuticals Ltd., expanded a recall of the ARB called losartan, which has been found to be contaminated with a different potential carcinogen called NMBA.(Updates with Italian recall starting in first paragraph.)To contact the reporter on this story: Anna Edney in Washington at firstname.lastname@example.orgTo contact the editors responsible for this story: Drew Armstrong at email@example.com, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.
NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Happify Health, a global leader in mental health technology, today announced it signed an agreement with global biopharmaceutical company Sanofi (SNY) to advance the application of digital therapeutics to address key co-morbidities for individuals living with multiple sclerosis (MS), including depression and anxiety. Happify Health will develop a version of its digital platform specifically for people with MS and plans to submit the co-developed digital therapy to the U.S. Food and Drug Administration for clearance as a medical device. "We've been preparing for our entry into prescription digital therapeutics for several years," said Ofer Leidner, co-founder and president of Happify Health.
Mainstream Media Starts Seeing Stark Central Banking Dilemma The mainstream media is starting to catch on to the fact that central banks might be toast, and not the lightly toasted kind that enhances flavor. More like the Cajun kind that turns everything black. Reuters opens an ominous report on the European Central Bank entitled “Draghi's […]The post Market Morning: Johnson Defies Benn, Saudi Oil Black Swan, Golden Toilet Heist appeared first on Market Exclusive.
A newly filed class-action lawsuit accuses international drug maker Sanofi of intentionally concealing risks in its popular heartburn medication, Zantac, which has been found to contain a carcinogenic chemical at 26,000 times the FDA-approved limit, according to the lawsuit filed by Hagens Berman. If you have taken Zantac, you may have ingested carcinogens. The lawsuit, filed Sept. 13, 2019, in the U.S. District Court for the Northern District of California accuses Sanofi and Boehringer Ingelheim of knowingly manufacturing and selling over-the-counter Zantac containing a concealed carcinogen to millions of people in the U.S. suffering from heartburn and other gastrointestinal issues, including sour stomach, acid reflux or gastroesophageal reflux disease (GERD).
A commonly used heartburn medicine from Sanofi, known as Zantac, could contain cancer-causing substances, the Food and Drug Administration said Friday. Sanofi stock fell a fraction.
Investing.com - U.S. and European health officials are investigating big-selling heartburn treatment Zantac and generics of the drug after a carcinogen was discovered in low levels, Bloomberg first reported Friday.
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
In addition to a $260 million payout, the drug dispute settlement returns worldwide development and commercialization rights to Houston-area firm.